Visualitza per autor "Burotto, Mauricio"
Ara mostrant els elements 1-3 d 3
-
Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma
Geynisman, Daniel M.; Burotto, Mauricio; Suárez Rodríguez, Cristina; Bourlon, Maria T.; Porta, Camillo; McGregor, Bradley (Oxford University Press, 2023-01) -
IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications
Burotto, Mauricio; Zvirbule, Z.; Mochalova, A.; Runglodvatana, Y.; Herraez-Baranda, L.; Liu, S.N.; FELIP, ENRIQUETA (Elsevier, 2023-08) -
Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma
Geynisman, Daniel M.; Burotto, Mauricio; Suárez Rodríguez, Cristina; Bourlon, Maria T.; Huo, Stephen; Porta, Camillo (Springer, 2022-07)